SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)

SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)

SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)

SC 13D/A - Lexaria Bioscience Corp. (0001348362) (Subject)

SC 13G/A - Lexaria Bioscience Corp. (0001348362) (Subject)

SC 13D - Lexaria Bioscience Corp. (0001348362) (Subject)

SC 13G/A - Lexaria Bioscience Corp. (0001348362) (Subject)

4 - Lexaria Bioscience Corp. (0001348362) (Issuer)

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups KELOWNA, BC / ACCESSWIRE / October 24, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) blood sugar results from the recently completed animal study WEIGHT-A24-1 (the "Study").Blood Sugar Levels (mmol/L)DehydraTECH GroupsDay 7 BaselineDay 28% Change to Day 28Day 56% Change to Day 56Day 84% Change to Day 84A: CBD127.426.2-4.31%26.9-1.90%27.71.09%B: CBD228.429.22.73%26.6-6.22%27.3-3.76%C: CBD326.424.9-5.99%27.12.46%27.53.85%D: CBD424.627.913.16%26.8

DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groupsAccelerated rates of weight loss were experienced during the final 4 weeks of the study in all DehydraTECH groups KELOWNA, BC / ACCESSWIRE / October 22, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has received partial 12-week (final) body weight results from the recently completed animal study WEIGHT-A24-1 (the "Study").Animal Weights (grams)DehydraTECHGroupsEnd ofAcclimationPeriodDay28% Changeto Day28Day56%Changeto Day56Day84%Changeto Day84A: CBD1427.9432.6+1.10%438.0+2.36%43

KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW))) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon

KELOWNA, BC / ACCESSWIRE / October 15, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 4,551,019 shares of common stock at an exercise price of $3.06 per share. The warrants will be exercisable beginning on the effective date of stockholder approval of the issuance of the sh

DehydraTECH-processed tirzepatide from Zepbound® is being tested in an oral dose format KELOWNA, BC / ACCESSWIRE / October 9, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) Zepbound® (tirzepatide) in an oral dose format.The Study is being conducted in up to 10 healthy volunteers. The initial seven day dosing phase of either an oral DehydraTECH-processed tirzepatide capsule or a

KELOWNA, BC / ACCESSWIRE / October 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements.In 2020 the total market size for GLP-1 drugs was less than $4 billion . That same year, Novo Nordisk® paid $1.8 billion to purchase Emisphere's® SNAC drug delivery technology which was subsequently incorporated into Rybelsus® semaglutide oral tablets, resulting in the first and only Food and Drug Administration ("FDA") approved GLP-1 drug for use as an oral tablet.Today, the GLP-1 market is growing faster than

KELOWNA, BC / ACCESSWIRE / October 1, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX) & (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations."Mike is an accomplished individual who brings a wealth of financial and regulatory knowledge and experience to the table," said Richard Christopher, Chief Executive Officer of Lexaria. "On behalf of the entire Lexaria team, I'm thrilled to welcome Mike as our CFO as we continue to strengthen our executive tea

First-ever DehydraTECH-processed tirzepatide from Zepbound® to be tested in a swallowed oral format KELOWNA, BC / ACCESSWIRE / September 27, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) tirzepatide in an oral dose format.Subject recruitment will begin shortly and the Company will announce as soon as the first dosing has begun, current

KELOWNA, BC / ACCESSWIRE / September 5, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer ("CEO") Chris Bunka as a strategic update to all stakeholders.CEO LETTER TO STAKEHOLDERSIt is with mixed emotions and a heavy heart that I write my final strategic letter to my Lexaria family. Lexaria has been "home" for 16 years, and, similar to raising a family, there have been difficult times that test your resolve, and many other times of incredible joy and pride.Many people will focus on the "why". There is just one, fairly simple reason: Lexa

KELOWNA, BC / ACCESSWIRE / September 3, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into a Material Transfer Agreement with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting.Under the terms of the agreement, Lexaria is responsible for formulation and supply of certain DehydraTECH compositions. The pharmacokinetics of DehydraTECH compositions will be evaluated in animal studies. Lexaria has awarded to PharmaCO a temporary exclusive license option limited to specific DehydraTECH concepts and formulations under exa

HC Wainwright & Co. analyst Yi Chen reiterates Lexaria Bioscience (NASDAQ:LEXX) with a Buy and maintains $10 price target.

- Reuters 

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces plans for strategic growth."Lexaria has certain initiatives underway that are increasing confidence in our medium-term and longer-term strategies," said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. "As a result of the success we are experiencing and the continued success we are anticipating, we will be implementing a number of strategic steps in the weeks and months to come."Lexaria will be expanding its management team this summer as it prepares for the greater workload of multiple projects and initiatives. The first step is appointin

Lexaria Bioscience (NASDAQ:LEXX) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.10) by 30 percent. This is a 64.86 percent increase over losses of $(0.37) per share from the same period last year. The company reported quarterly sales of $84.00 thousand which missed the analyst consensus estimate of $150.00 thousand by 44.00 percent. This is a 8.10 percent increase over sales of $77.71 thousand the same period last year.

HC Wainwright & Co. analyst Yi Chen initiates coverage on Lexaria Bioscience (NASDAQ:LEXX) with a Buy rating and announces Price Target of $10.

Lexaria currently holding 46 granted patents worldwideKELOWNA, BC / ACCESSWIRE / July 8, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces three new patent awards.In the European Union, the Company has received a new granted patent in Lexaria's patent family #6: Transdermal and/or Dermal Delivery of Lipophilic Active Agents. This is the Company's second granted patent in this patent family with an earlier patent granted in Canada. This patent will expire in 2039, if not extended and was validated in the following countries: Austria, Czech Republic, France, UK, Germany, Italy, Poland, Spain, Sweden

Shares of Healthequity Inc (NASDAQ:HQY) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results. The company reported quarterly earnings of 80 cents per share which beat the analyst consensus estimate of 66 cents, according to data from Benzinga Pro. HealthEquity issued strong FY25 earnings guidance and also issued FY25 revenue guidance with its midpoint above expectations. Healthequity shares jumped 5.9% to $85.98 in the pre-market trading session. Here are some other stocks moving in pre-market trading. Gainers MicroAlgo Inc (NASDAQ:MLGO) rose 209.5% to $4.83 in today's pre-market trading. WiMi Hologram Cloud a

Gainers Cue Health (NASDAQ:HLTH) shares rose 70.1% to $0.09 during Thursday's regular session. The market value of their outstanding shares is at $14.8 million. OneMedNet (NASDAQ:ONMD) shares increased by 29.23% to $2.52. The company's market cap stands at $60.1 million. iSpecimen (NASDAQ:ISPC) shares moved upwards by 22.87% to $0.39. The company's market cap stands at $3.8 million. Xeris Biopharma Holdings (NASDAQ:XERS) shares increased by 18.13% to $2.28. The market value of their outstanding shares is at $338.0 million. Kintara Therapeutics (NASDAQ:KTRA) stock rose 18.01% to $0.32. The market value of their outstanding shares is at $17.7 million. Lexaria Bioscience (NASDAQ:LEXX) sha